Veteran private-equity and healthcare operator focused on scaling specialty pharma and services businesses across North America and Europe. Alan Rosenfield brings corporate-development and M&A experience, advising boards on commercialization strategy, licensing and carve-outs while overseeing portfolio-company performance and capital allocation. Known for operational rigor, deal execution and post-acquisition integration, frequently active as an investor, board director and interim CRO/CBO in growth-stage healthcare companies.
Veteran private-equity and healthcare operator focused on scaling specialty pharma and services businesses across North America and Europe. Alan Rosenfield brings corporate-development and M&A experience, advising boards on commercialization strategy, licensing and carve-outs while overseeing portfolio-company performance and capital allocation. Known for operational rigor, deal execution and post-acquisition integration, frequently active as an investor, board director and interim CRO/CBO in growth-stage healthcare companies.
Operates a hands-on, value‑creation approach focused on mid-market specialty pharma and healthcare services in North America and Europe. Prioritizes platform investments and buy-and-build roll-ups where operational playbooks, commercialization acceleration, licensing optimization and disciplined capital allocation drive EBITDA expansion. Investment style blends private‑equity control or minority-stewardship with active board roles and interim commercial leadership, targeting scalable revenue growth and margin improvement over a medium-term (3–5 year) hold period.
Operates a hands-on, value‑creation approach focused on mid-market specialty pharma and healthcare services in North America and Europe. Prioritizes platform investments and buy-and-build roll-ups where operational playbooks, commercialization acceleration, licensing optimization and disciplined capital allocation drive EBITDA expansion. Investment style blends private‑equity control or minority-stewardship with active board roles and interim commercial leadership, targeting scalable revenue growth and margin improvement over a medium-term (3–5 year) hold period.
| Trades 1412 | Longs Won 1038/1412 73% | Profit Factor 8.34 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $621,442.29 |
| Average Win $129,143.46 | Best Trade (Jul 15) $16.41M | Sharpe Ratio -9.71 |
| Average Loss -$42,967.31 | Worst Trade (Sep 30) -$3.06M | Z-Score 16.18 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 2w 1d | Expectancy $83,556.04 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 8,772 | 7,895 | 7,018 | 6,140 | 5,263 | 4,386 | 3,509 | 2,632 | 1,754 | 877 |